Paraoxonase promoter polymorphism T(-107)C and relative paraoxonase deficiency as determinants of risk of coronary artery disease

Journal of Molecular Medicine

Volumn 79, Issue 8, 2001, Pages 457-463

  Leviev, Ilia ^a   Righetti, Alberto ^a   James, Richard W ^a  

^a UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Anti oxidant; Coronary disease; Gene polymorphism; High density lipoprotein; Oxidative stress

Indexed keywords

ARYLDIALKYLPHOSPHATASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; ENZYME ACTIVITY; ENZYME DEFICIENCY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PROMOTER REGION; RISK FACTOR;

AGED; AGING; ARYLDIALKYLPHOSPHATASE; CHOLESTEROL; CHOLESTEROL, HDL; CORONARY DISEASE; ESTERASES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); TRIGLYCERIDES;

EID: 0034880694     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001090100240     Document Type: Article

References (46)

1. Low density lipoprotein oxidation and its pathobiological significance
2. High density lipoproteins and coronary heart disease
3. Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase
4. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein
5. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase
6. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidised low density lipoprotein
7. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis
8. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response
9. Overexpression of apolipoprotein A-II in transgenic mice converts high density lipoproteins to pro-inflammatory particles
10. The polymorphism (Gln-Arg192) of the high-density lipoprotein-bound enzyme paraoxonase is an independent cardiovascular risk factor in non-insulin dependent diabetic patients
11. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes
12. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary heart disease
13. Genetic polymorphisms of paraoxonase and the risk of coronary heart disease
14. 192Arg variant of the human paraoxonase (HUMPONA) gene polymorphism is associated with an increased risk for coronary artery disease in the Japanese
15. Paraoxonase polymorphism (Gln192-Arg) is associated with coronary heart disease in Japanese noninsulin-dependent diabetic patients
16. Paraoxonase PON1 polymorphism leu-Met54 is associated with carotid atherosclerosis: Results of the Austrian Stroke Prevention Study
17. Paraoxonase 192 Gln/Arg gene polymorphism, coronary artery disease, and myocardial infarction in type 2 diabetes
18. Polymorphism in high density lipoprotein paraoxonase gene and risk of acme myocardial infarction in men: Prospective nested case-control study
19. The Gln-Arg191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with risk of coronary artery disease in Finns
20. The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM study
21. Paraoxonase gene polymorphism in Japanese subjects with coronary heart disease
22. The paraoxonase Gln-Arg 192 polymorphism in subjects with ischaemic heart disease
23. Mutations in the human paraoxonase 1 gene: Frequencies, allelic linkages, and association with coronary artery disease
24. Evidence for association between paraoxonase gene polymorphisms and atherosclerotic diseases
25. Promoter polymorphisms of the human paraoxonase PON1 gene and serum paraoxonase activities and concentrations
26. The promoter polymorphism T(-107) C of the paraoxonase PON1 gene is a risk factor for coronary heart disease in type 2 patients
27. Smoking is associated with reduced serum paraoxonase activity and concentration in coronary artery disease patients
28. Differences in lipoprotein subfraction composition and distribution between type 1 diabetic men and control subjects
29. The distribution profiles of very low density and low density lipoproteins in poorly-controlled male, type 2 (non-insulin-dependent) diabetic patients
30. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
31. Quantification of human serum paraoxonase by enzyme-linked immunoassay: Population differences in protein concentrations
32. Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation
33. Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients
34. A case-control study of lipoprotein particles in two populations at contrasting risk for coronary heart disease. The ECTIM Study
35. Cholesterol lowering in the elderly population. Coordinating Committee of the National Cholesterol Education Program
36. Modulated serum activities and concentrations of paraoxonase in high density lipoprotein deficiency states
37. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: Glutamine or arginine at position 191, for the respective A or B allozymes
38. The molecular basis of the human serum paraoxonase activity polymorphism
39. Human serum paratxonase (PON1) is inactivated by oxidised low density lipoprotein and preserved by antioxidants
40. Lipid research clinics program reference values for hyperlipidemia and hypolipidemia
41. Aging: Is oxidative stress a marker or is it causal?
42. Paraoxonase (PON1) phenotype is a better predictor of vascular disease than Is PON1(192) or PON1(55) genotype
43. Alloenzymes of paraoxonase and effectiveness of high-density lipoproteins in protecting low-density lipoproteins against lipid oxidation
44. Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities
45. Mildly oxidised LDL induces an increased apolipoprotein J/paraoxonase ratio
46. Paraoxonase protection of LDL against peroxidation is independent of its esterase activity towards paraoxon and is unaffected by the Q-R genetic polymorphism